OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
ImmunoCellular To Present Encouraging Phase 1 Study Results For Brain Tumour Treatment
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.
Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
The fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by UV exposure or excessive sun burn.
Threshold Pharmaceuticals Selectively Targets Tumor Cells in Cancer Therapeutics
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.
Provectus Pharmaceuticals Uses Old Drug To Actualize Novel Therapeutics for Cancer and Skin Disorders
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
Cynvenio Biosystems Selected as 2011 FiReStarter Company
Strategic News Service recently announced that Cynvenio Biosystems has been selected as a 2011 FiReStarter company, to be featured at its annual Future in Review technology conference.
